Dr.Jacek Rozga Invited to Present Rationale for the SEPET(TM) Liver Assist Device WALTHAM, Mass., Dec. 5 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC:ABOS), a company developing proprietary medical devices and cell-based therapies for the millions of patients each year who experience or are at risk for life-threatening episodes of liver failure, today announced that Jacek Rozga, M.D., Ph.D., Founder and Chief Scientific Officer, has been invited to present at The Acute Liver Failure Workshop, which began yesterday and continues today at the Hyatt Regency Bethesda, in Bethesda, MD. The meeting is sponsored by the Liver Disease Research Branch of the Division of Digestive Diseases and Nutrition of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), in collaboration with the Food and Drug Administration (FDA) and other federal agencies. Dr. Rozga's presentation, entitled, "Plasma Filtration Therapy of Acute Liver Failure, takes place this morning, December 5th at 10:50 a.m. Eastern Time. His presentation focused on rationales for use of Arbios' SEPET(TM) Liver Assist Device technology for removal from the blood of small and middle molecular weight molecules, including inflammatory cytokines and conventional toxins including those bound to albumin, which are implicated in poor patient outcomes from acute liver failure. Dr. Rozga will further address rationales for potential benefit of SEPET(TM) plasma filtration therapy in the treatment of conditions related to, and often arising as a result of, liver failure, including multi-organ failure, systemic inflammatory response syndrome, and severe sepsis. Dr. Rozga will also summarize the previously announced favorable progress of Arbios' ongoing feasibility clinical trial of the SEPET(TM) Liver Assist Device. About The Acute Liver Failure Workshop To aim of the Acute Liver Failure Meeting, which brings together some of the best scientific minds in the medical community, is to assess current knowledge about acute liver failure, including its causes, incidence, natural history, management, and prevention. The meeting will also make recommendations for directions for future research, both basic and clinical. Topics will include: epidemiology; current causes and secular trends in distribution of etiologies; natural history and course; specific and nonspecific management; acetaminophen as a cause of liver injury and intentional vs. unintentional acetaminophen overdose; causes of acute liver injury in children and the role of acetaminophen; autoimmunity as a cause of acute liver failure; changes in frequency of viral hepatitis as a cause of acute liver failure; liver transplantation, including living donor liver transplantation; innovative therapies for acute liver failure including hypothermia and role of bioartificial liver support systems and albumin dialysis. The workshop will also focus on needs for future research. About Arbios Systems Arbios Systems, Inc. is developing proprietary medical devices and cell- based therapies to enhance the survival of millions of patients each year who experience, or are at risk for, life-threatening episodes of liver failure. The Arbios product candidate portfolio includes the SEPET(TM) Liver Assist Device, a novel blood purification therapy that provides enhanced "liver dialysis," and the HepatAssist(TM) Cell-Based Liver Support System, a bioartificial liver that combines blood detoxification with liver cell therapy to replace whole liver function in patients with the most severe forms of liver failure. This press release contains forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the goals and results of clinical trials, compliance with regulatory requirements, labeling of the Company's products, the need for subsequent substantial additional financing to complete clinical development of its products, future markets and demand for the Company's products, and Arbios' ability to successfully market its products and technologies. These statements represent the judgment of Arbios' management as of this date and are subject to risks and uncertainties that could materially affect the Company. Arbios cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements. Please refer to our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005 for a description of risks that may affect our results or business conditions. The Company does not undertake any obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. SEPET(TM) and HepatAssist(TM) are trademarks of Arbios Systems, Inc. DATASOURCE: Arbios Systems, Inc. CONTACT: Walter C. Ogier, of Arbios Systems, Inc., +1-781-839-7293, ; or Doug MacDougall, MacDougall Biomedical Communications, +1-508-647-0209; Investors - Paula Schwartz, +1-917-322-2216, Media - Pat Garrison, +1-917-322-2567, both of RX Communications Group Web site: http://www.arbios.com/

Copyright